Cargando…

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial

AIMS: Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower three quartiles [Q1–Q3] vs. the upper quartile...

Descripción completa

Detalles Bibliográficos
Autores principales:	Senni, Michele, Lopez‐Sendon, Jose, Cohen‐Solal, Alain, Ponikowski, Piotr, Nkulikiyinka, Richard, Freitas, Cecilia, Vlajnic, Vanja Miodrag, Roessig, Lothar, Pieske, Burkert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773767/ https://www.ncbi.nlm.nih.gov/pubmed/35880474 http://dx.doi.org/10.1002/ehf2.14050

Ejemplares similares

Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
por: Voors, Adriaan A., et al.
Publicado: (2021)

Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021)

NT-proBNP and diastolic left ventricular function in patients with Marfan syndrome
por: Gehle, Petra, et al.
Publicado: (2016)

Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
por: Pieske, Burkert, et al.
Publicado: (2017)

Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables
por: Curiati, Milena Novaes Cardoso, et al.
Publicado: (2013)

Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction
por: Salah, Khibar, et al.
Publicado: (2019)

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
por: Palazzuoli, A, et al.
Publicado: (2010)

The Ability of Heart Failure Specialists to Accurately Predict NT-proBNP Levels Based on Clinical Assessment and a Previous NT-proBNP Measurement
por: Sedlak, Tara L, et al.
Publicado: (2008)

Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction
por: Daubert, Melissa A., et al.
Publicado: (2021)

NT‐proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials
por: Werhahn, Stefanie M., et al.
Publicado: (2021)

BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
por: Lewis, Robert A., et al.
Publicado: (2020)

Use of NT-proBNP in weaning from mechanical ventilation
por: Martini, A, et al.
Publicado: (2011)

NT-proBNP and the diagnosis of exercise-induced myocardial ischaemia
por: De Greef, Jacques, et al.
Publicado: (2008)

Rise and fall of NT-proBNP in aortic valve intervention
por: Hultkvist, Henrik, et al.
Publicado: (2018)

Highly sensitive detection of NT-proBNP by molecular motor
por: Zhang, Jie, et al.
Publicado: (2016)

In-hospital mortality is associated with high NT-proBNP level
por: Benmachiche, Malik, et al.
Publicado: (2018)

Admission NT-ProBNP in Myocardial Infarction: an Alert Sign?
por: da Silva, Luís Beck
Publicado: (2019)

The Potential Role of Salivary NT-proBNP in Heart Failure
por: Rammos, Aidonis, et al.
Publicado: (2023)

Baseline NT-proBNP and responsiveness to autonomic regulation therapy in patients with heart failure and reduced ejection fraction
por: Anand, Inder, et al.
Publicado: (2020)

Can NT-proBNP Levels Be an Early Biomarker of Reduced Left Ventricular Ejection Fraction in Preterm Infants?
por: Lin, Ya-Lan, et al.
Publicado: (2022)

BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine
por: Cao, Zhipeng, et al.
Publicado: (2019)

Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors
por: Alawieh, Hussein, et al.
Publicado: (2019)

Does dipyridamole-induced ischaemia affect NT-proBNP secretion?
por: De Greef, Jacques, et al.
Publicado: (2007)

Using NT-proBNP as a criterion for heart failure hospitalization
por: Tamizifar, Babak, et al.
Publicado: (2012)

NT-proBNP in Children With Left to Right Shunt and Dilated Cardiomyopathy
por: Koura, Hala Mahmoud, et al.
Publicado: (2016)

The relationship between NT-proBNP and Depression in Patients with Heart Failure
por: Gao, Ying–Hui, et al.
Publicado: (2017)

NT-proBNP as a biomarker for hyperdynamic circulation in decompensated cirrhosis
por: Maslennikov, Roman, et al.
Publicado: (2018)

NT-proBNP and postoperative heart failure in surgery for aortic stenosis
por: Jiang, Huiqi, et al.
Publicado: (2019)

Significance of NT-proBNP and High-Sensitivity Troponin in Friedreich Ataxia
por: Legrand, Lise, et al.
Publicado: (2020)

Prognostic value of NT-proBNP in patients with severe COVID-19
por: Gao, Lei, et al.
Publicado: (2020)

Performance of the Abbott Architect Immuno-Chemiluminometric NT-proBNP Assay
por: Lau, Chin-Shern, et al.
Publicado: (2022)

LSPR-Based Aptasensor for Rapid Urinary Detection of NT-proBNP
por: António, Maria, et al.
Publicado: (2023)

Clinical characteristics and outcomes of patients hospitalized with heart failure with preserved ejection fraction and low NT-proBNP levels
por: Chen, Yu-Yi, et al.
Publicado: (2023)

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure
por: Linssen, G. C. M., et al.
Publicado: (2018)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

NT-proBNP levels in the ICU do not predict the etiology of respiratory distress
por: Mailloux, P, et al.
Publicado: (2006)

NT-ProBNP Levels in Saliva and Its Clinical Relevance to Heart Failure
por: Foo, Jared Yong Yang, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_siridlp39soj5u7o2kitq81vqn